Impact of Superselective Transarterial Infusion Therapy of High-Dose Cisplatin on Maxillary Cancer with Orbital Invasion

BACKGROUND AND PURPOSE: We have been performing the superselective transarterial infusion of high-dose cisplatin for advanced maxillary cancer since 1998 and the local control rate, disease free survival rate, and organ preservation have improved markedly compared with our former therapy. This study evaluates the effectiveness of superselective transarterial infusion therapy by using high-dose cisplatin on maxillary cancer with orbital invasion. MATERIALS AND METHODS: We treated 23 patients with maxillary cancer by using superselective transarterial infusion therapy with high-dose cisplatin and concomitant radiation therapy for 10 years. Of all patients, 15 showed orbital invasion, with 11 of these tumors fed by both internal maxillary and ophthalmic arteries. In all patients, we performed superselective transarterial infusion therapy via the internal maxillary artery and/or the other feeding branches from the external carotid artery. After the operation, we determined whether a pCR had occurred by checking for the presence of viable cells. In addition, we calculated the overall survival rate, preservation rate of the eyeball, and disease-free survival rate. RESULTS: For all 23 patients, pCR and overall survival rates were 95.7% and 78.4%, respectively. To date, 2 of these patients died of lung metastasis without local recurrence. For the 15 patients with orbital invasion, the respective pCR and disease-free survival rates were 93.3% and 87.5%. Eyeballs were preserved in all patients, and local recurrence occurred in only 1 patient, at the inferior wall of the maxillary sinus (not in the orbit). CONCLUSIONS: Superselective transarterial infusion therapy with high-dose cisplatin remarkably improved the local control rate and disease-free survival rate of maxillary cancer. Even in patients with orbital invasion, a high local control rate was achieved, with preservation of the eyeball, through infusion only into branches of the external carotid artery.

[1]  J. A. Navarro,et al.  The Nasal Cavity and Paranasal Sinuses , 2012, Springer Berlin Heidelberg.

[2]  S. Fukuda,et al.  Superselective high‐dose cisplatin infusion with concomitant radiotherapy in patients with advanced cancer of the nasal cavity and paranasal sinuses , 2009, Cancer.

[3]  Mika Watanabe,et al.  Combined therapy after superselective arterial cisplatin infusion to treat maxillary squamous cell carcinoma , 2007, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[4]  Kichinobu Tomita,et al.  Efficacy of Intra-Arterial Infusion Chemotherapy for Head and Neck Cancers Using Coaxial Catheter Technique: Initial Experience , 2007, CardioVascular and Interventional Radiology.

[5]  N. Hayashi,et al.  A new aspect of tri-modal therapy with superselective intra-arterial chemotherapy in maxillary sinus carcinoma , 2007, Acta oto-laryngologica. Supplementum.

[6]  O. Matsui,et al.  Feeding Artery of Laryngeal and Hypopharyngeal Cancers: Role of the Superior Thyroid Artery in Superselective Intraarterial Chemotherapy , 2006, CardioVascular and Interventional Radiology.

[7]  J. Wan,et al.  Intra-arterial cisplatin and concomitant radiation therapy followed by surgery for advanced paranasal sinus cancer. , 2004, Archives of otolaryngology--head & neck surgery.

[8]  J. Yokoyama.  [Usefulness of CT-angiography for superselective intra-arterial chemotherapy for advanced head and neck cancers]. , 2002, Gan to kagaku ryoho. Cancer & chemotherapy.

[9]  M. Miura,et al.  Trimodal combination therapy for maxillary sinus carcinoma. , 2002, International journal of radiation oncology, biology, physics.

[10]  N. Kawahara,et al.  Results of multimodality therapy for squamous cell carcinoma of maxillary sinus , 2002, Cancer.

[11]  S. Ehara,et al.  Superselective continuous arterial infusion chemotherapy through the superficial temporal artery for oral cavity tumors. , 2000, AJNR. American journal of neuroradiology.

[12]  M. Kaplan,et al.  Lymph node metastasis in maxillary sinus carcinoma. , 2000, International journal of radiation oncology, biology, physics.

[13]  T. Murry,et al.  A novel organ preservation protocol for advanced carcinoma of the larynx and pharynx. , 1996, Archives of otolaryngology--head & neck surgery.

[14]  S. Howell,et al.  A targeted supradose cisplatin chemoradiation protocol for advanced head and neck cancer. , 1994, American journal of surgery.

[15]  S. Howell,et al.  Phase I study of highly selective supradose cisplatin infusions for advanced head and neck cancer. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  S. Howell,et al.  Rapid superselective high‐dose cisplatin infusion for advanced head and neck malignancies , 1992, Head & neck.

[17]  J. Guy,et al.  Central retinal and posterior ciliary artery occlusion after particle embolization of the external carotid artery system. , 1991, Ophthalmology.

[18]  C. Perez,et al.  Principles and Practice of Radiation Oncology , 1987 .

[19]  B. Teicher,et al.  Characterization of a human squamous carcinoma cell line resistant to cis-diamminedichloroplatinum(II). , 1987, Cancer research.

[20]  D. V. Von Hoff,et al.  Use of in vitro dose response effects to select antineoplastics for high-dose or regional administration regimens. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  H. Niitani,et al.  Effects of sodium thiosulfate in combination therapy of cis-dichlorodiammineplatinum and vindesine , 2004, Cancer Chemotherapy and Pharmacology.

[22]  S. Howell,et al.  Selective intra-arterial infusion of high-dose cisplatin in patients with advanced head and neck cancer results in high tumor platinum concentrations and cisplatin-DNA adduct formation , 2004, Cancer Chemotherapy and Pharmacology.

[23]  Kazuhiro Hotta,et al.  Effects of sodium thiosulfate on the pharmacokinetics of unchanged cisplatin and on the distribution of platinum species in rat kidney: protective mechanism against cisplatin nephrotoxicity , 2004, Cancer Chemotherapy and Pharmacology.